Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 80

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 80
---
,460 $28,460 $— $— Money market funds87,388 87,388 — — Marketable securitiesCorporate debt securities337,747 — 337,747 — U.S government agency securities9,995 09,995 0Other noncurrent assetsMarketable securities - restricted (SERP)617 23 594 — Total assets at fair value$464,207 $115,871 $348,336 $— Liabilities:Contingent consideration$30,000 $30,000 $— $— Total liabilities at fair value$30,000 $30,000 $— $— Fair Value Measurements as of December 31, 2024TotalLevel 1 Level 2Level 3Assets:Cash and cash equivalentsCash$37,830 $37,830 $— $— Money market funds31,501 31,501 — — Marketable securitiesCorporate debt securities355,201 — 355,201 — U.S. government agency debt securities29,080 029,080 0Other noncurrent assetsMarketable securities - restricted (SERP)635 21 614 — Total assets at fair value$454,247 $69,352 $384,895 $— Liabilities:Contingent consideration$47,340 $— $— $47,340 Total liabilities at fair value$47,340 $— $— $47,340 Other Financial Instruments

11

The carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses approximate fair value due to their short-term maturities. 

6. Contingent Consideration

The following table sets forth the contingent consideration for the USWM Acquisition and Adamas Acquisition (as defined below) (dollars in thousands):March 31,2025December 31,2024(unaudited)Reported under the following captions in the consolidated balance sheets:Contingent consideration, current portion$30,000 $47,340 Total$30,000 $47,340 The Company's contingent consideration liabilities are related to the USWM Acquisition in 2020 and the Adamas Acquisition in 2021. The contingent consideration liabilities are measured at fair value using either a Monte Carlo simulation or the income approach.